Clinical Trial Update: OGX-427 in Castration Resistant Prostate Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of OGX-427 (apatorsen) in castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• OGX-427 (apatorsen)

Snippet

Sponsor: British Columbia Cancer Agency | Conditions: Castration Resistant Prostate Cancer | Phase 2 | Status: COMPLETED